Avalo Therapeutics (AVTX)
(Delayed Data from NSDQ)
$12.59 USD
+0.95 (8.16%)
Updated Jul 5, 2024 03:39 PM ET
After-Market: $12.34 -0.25 (-1.99%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Industry / Sector Report
Industry : Medical - Drugs
Zacks Industry Rank
Top 39% (98 out of 249)Zacks Sector Rank
Top 31% (5 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.00 | 1.52 | 9.99 |
Current Quarter Estimate | -0.19 | -2.04 | 61.00 |
Year Ago Quarter Estimate | -140.48 | -0.59 | 54.84 |
Next Quarter Estimate | -0.36 | -2.00 | 63.00 |
Next Year Estimate | -0.97 | 6.92 | 270.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 99.20 | 14.00 | 15.67 |
Next Year | -6.59 | 15.00 | 9.31 |
Last 5 Years | NA | 7.00 | 8.10 |
Next 5 Years | NA | 25.10 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -5.88 |
Price/Book (MRQ) | NA | 1.74 |
Price/Cash Flow (MRFY) | NA | 7.93 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -1,639.50% | -2,822.50% |
Return on Equity (TTM) | -1,439.87% | -71.77% |
Debt to Equity (MRQ) | NA | 0.08 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.